A prior section 216 of this title, Pub. L. 107–296, title IV, § 416, Nov. 25, 2002, 116 Stat. 2181, related to GAO report to Congress, prior to repeal by Pub. L. 114–125, title VIII, § 802(f), Feb. 24, 2016, 130 Stat. 210.

2022—Subsec. (b)(1)(C). Pub. L. 117–263, § 7135(a), added subpar. (C).

Subsec. (c). Pub. L. 117–263, § 7135(b), inserted “, containment devices,” after “equipment” in heading and substituted “, opioid receptor antagonists, including naloxone, and containment devices” for “and opioid receptor antagonists, including naloxone” in text.

Pub. L. 117–263, div. G, title LXXI, § 7135(c), Dec. 23, 2022, 136 Stat. 3650, provided that: “If the Secretary of Homeland Secretary determines that officers, agents, other personnel, or canines of a component of the Department of Homeland Security other than U.S. Customs and Border Protection are at risk of potential synthetic opioid exposure in the course of their duties, the head of such component shall carry out the responsibilities under section 416 of the Homeland Security Act of 2002 (6 U.S.C. 216) in the same manner and to the same degree as the Commissioner of U.S. Customs and Border Protection carries out such responsibilities.”